Antitumor angiogenesis-targeted drugs can inhibit the vascular endothelial growth factor receptor (vascular endothelial growth, VEGFR) signal transduction pathway, acting on the angiogenic factors released by endothelial cells or surrounding stromal cells, thereby promoting the normalization of tumor blood vessels. The gene discussed is KDR; the disease is neoplasm.